C4 therapeutics announces chief financial officer succession

Watertown, mass., sept. 05, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of kendra adams as chief financial officer (cfo), effective september 18, 2023. she will succeed lauren white, who will be leaving c4t to pursue a new role with a commercial-stage pharmaceutical company.
CCCC Ratings Summary
CCCC Quant Ranking